217 reports of this reaction
1.8% of all ENFORTUMAB VEDOTIN reports
#15 most reported adverse reaction
HYPERGLYCAEMIA is the #15 most commonly reported adverse reaction for ENFORTUMAB VEDOTIN, manufactured by SEAGEN INC.. There are 217 FDA adverse event reports linking ENFORTUMAB VEDOTIN to HYPERGLYCAEMIA. This represents approximately 1.8% of all 12,251 adverse event reports for this drug.
Patients taking ENFORTUMAB VEDOTIN who experience hyperglycaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERGLYCAEMIA is a less commonly reported adverse event for ENFORTUMAB VEDOTIN, but still significant enough to appear in the safety profile.
In addition to hyperglycaemia, the following adverse reactions have been reported for ENFORTUMAB VEDOTIN:
The following drugs have also been linked to hyperglycaemia in FDA adverse event reports:
HYPERGLYCAEMIA has been reported as an adverse event in 217 FDA reports for ENFORTUMAB VEDOTIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERGLYCAEMIA accounts for approximately 1.8% of all adverse event reports for ENFORTUMAB VEDOTIN, making it a notable side effect.
If you experience hyperglycaemia while taking ENFORTUMAB VEDOTIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.